CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is designed to educate patients about metastatic triple-negative breast cancer (mTNBC), a distinct subtype of breast cancer.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS ACTIVITY
  Audio Program: This activity consists of an audio component. The participant may review the faculty information, listen to the MP3s and review the downloadable slide set, located at ResearchToPractice.com/PatientProject2024/mTNBCPatients. The corresponding video program is available as an alternative at ResearchToPractice.com/PatientProject2024/mTNBCPatients/Video.
  
  Video Program: This activity consists of a video component. The participant may review the faculty information and watch the video located at ResearchToPractice.com/PatientProject2024/mTNBCPatients/Video. The corresponding audio program is available as an alternative at ResearchToPractice.com/PatientProject2024/mTNBCPatients.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Lisa A Carey, MD, ScM, FASCO
  L Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
  Deputy Director for Clinical Sciences
  Lineberger Comprehensive Cancer Center
  University of North Carolina
  Chapel Hill, North Carolina
  
  No relevant conflicts of interest to disclose.
  
  Rita Nanda, MD
  Director, Breast Oncology
  Associate Professor of Medicine
  Section of Hematology/Oncology
  The University of Chicago
  Chicago, Illinois
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, GE Healthcare, Gilead Sciences Inc, Guardant Health, Merck, Moderna, Novartis, OBI Pharma Inc, Pfizer Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Corcept Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Relay Therapeutics, Seagen Inc, Sun Pharmaceutical Industries Ltd, Taiho Oncology Inc.
  
  SURVEY PARTICIPANTS — Adam M Brufsky, MD, PhD — Consulting Agreements: Agendia Inc, AstraZeneca Pharmaceuticals LP, BriaCell, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Sanofi; Joyce O’Shaughnessy, MD — Advisory Committees and Consulting Agreements: Aadi Bioscience, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Ellipses Pharma, Exact Sciences Corporation, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, HiberCell, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics, Tempus, TerSera Therapeutics LLC; Priyanka Sharma, MD — Advisory Committees: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, GSK, Menarini Group, Merck, Novartis, Pfizer Inc, Sanofi; Consulting Agreements: Gilead Sciences Inc, Menarini Group, Merck; Contracted Research: Bristol Myers Squibb, Gilead Sciences Inc, Novartis; Data and Safety Monitoring Boards/Committees: Jazz Pharmaceuticals Inc; Seth Wander, MD, PhD — Advisory Committees: Biovica International AB, Genentech, a member of the Roche Group, Hologic Inc, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Foundation Medicine, Lilly, Novartis; Contracted Research: Genentech, a member of the Roche Group, Lilly, Nuvation Bio, Pfizer Inc, Regor Therapeutics Group, Sermonix Pharmaceuticals; Data and Safety Monitoring Board/Committees: Regor Therapeutics Group; Speakers Bureaus: Guardant Health, Lilly; Nonrelevant Financial Relationships: 2nd.MD.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from Gilead Sciences Inc.
  
  Release date: January 2025
  Expiration date: January 2026